Response to platelet antiaggregation in patients with ischemic heart disease treated at the "Abel Santamaría Cuadrado" General Teaching Hospital

Abstract

Introduction: platelet antiaggregant are part of the treatment of patients with ischemic heart disease. Objective: to characterize the response of platelet antiaggregant in patients with ischemic heart disease. Methods: observational, descriptive and cross-sectional study in patients with ischemic heart disease treated at the "Abel Santamaría Cuadrado" General Teaching Hospital between January 2018 and November 2019. The sample consisted of 146 patients receiving standard doses of ASA (tablet 125 mg ). The patients were randomly distributed into two groups: ASA groups (n= 73) and the ASA + clopidogrel group (n= 73). Results: male sex (60,9 %) and dyslipidemia as a risk factor (74,6 %) predominated. A greater number of patients without response to aggregation was found in the patients of the ASA group (10,3 % vs 6,8 %). The main risk factors for non-responders were obesity (ASA: 70,6 % vs ASA + clopidogrel: 75 %) and diabetes mellitus (ASA: 70,6 % vs ASA + clopidogrel: 87,5 %). The largest number of non-responders had an LVEF < 30 % (10,3 % of patients). Conclusions: therapeutics with ASA and ASA + clopidogrel achieve adequate platelet antiaggregation in patients with ischemic heart disease. Patients who receive only ASA tend to present a null response to antiaggregant therapy to a greater extent. Non-responders to antiaggregant therapy were mostly diabetic and obese, with a history of acute coronary syndrome and a reduced left ventricular ejection fraction.

Keywords

• isquemia miocárdica
• enfermedad coronaria
• cardiopatías
• inhibidores de agregación plaquetaria
• clopidogrel
• aspirina.